Status:

COMPLETED

Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration

Lead Sponsor:

Direction Centrale du Service de Santé des Armées

Conditions:

Dry Eye Syndromes

Age-Related Macular Degeneration

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Age-related macular degeneration (AMD) is the 1st cause of visual impairment after the age of 50. Its most aggressive form, wet AMD, requires regular intravitreal injections (IVI) spaced 4 to 8 weeks ...

Eligibility Criteria

Inclusion

  • Adult patient treated for exudative AMD with at least one eye receiving IVI with an anti-VEGF for at least 12 months.
  • Patient with at least one untreated dry eye symptom.
  • Only one eye is included per patient. For patients injected bilaterally, the eye with the lowest TBUT will be included, otherwise the one with the highest Oxford score, otherwise the one with the lowest Schirmer score. If these 3 parameters are similar, the right eye will be included by default.
  • Patient who has given informed consent to participate and understands the information related to the study.
  • Patient affiliated with a social security plan or beneficiary of such a plan.
  • Concurrent participation in non-interventional research is allowed. Concurrent participation in interventional research may be evaluated on a case-by-case basis by the Principal Investigator.

Exclusion

  • Patients with meatus plugs at inclusion.
  • Eye surgery ≤ 3 months pre-inclusion (including laser or refractive).
  • Anticholinergic\* treatment prior to inclusion.
  • Patients unable to maintain follow-up during the study period.
  • Evidence of active ocular infection in either eye.
  • History or presence of non-drying ocular surface disorders in either eye.
  • Trauma or surgery to the eyelids.
  • Any ocular or systemic pathology or treatment identified by the Investigator as likely to interfere with the results of the study.
  • Hypersensitivity to any component of the medical device.

Key Trial Info

Start Date :

October 9 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 14 2024

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT06174181

Start Date

October 9 2023

End Date

November 14 2024

Last Update

February 25 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Hopital Avicenne

Bobigny, France, 93000

2

HIA Desgenettes

Lyon, France, 69003

Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration | DecenTrialz